m6A-centered Disease Response Information

General Information of the Disease (ID: M6ADIS0176)
Name
Endocrine glands benign cancer
ICD
ICD-11: 2F37
Full List of Target Gene(s) of This m6A-centered Disease Response
Cytokine-responsive protein CR6 (GADD45-Gamma)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [1]
Response Summary METTL3 promotes tumor growth and hormone secretion by increasing expression of GNAS and Cytokine-responsive protein CR6 (GADD45-Gamma) in a m6A-dependent manner. Thus, METTL3 and the methylated RNAs constitute suitable targets for clinical treatment of Pituitary growth hormone-secreting-pituitary adenomas(GH-PAs).
Responsed Disease Endocrine glands benign cancer [ICD-11: 2F37]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Guanine nucleotide-binding protein G (GNAS)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [1]
Response Summary METTL3 promotes tumor growth and hormone secretion by increasing expression of Guanine nucleotide-binding protein G (GNAS) and GADD45-Gamma in a m6A-dependent manner. Thus, METTL3 and the methylated RNAs constitute suitable targets for clinical treatment of Pituitary growth hormone-secreting-pituitary adenomas(GH-PAs).
Responsed Disease Endocrine glands benign cancer [ICD-11: 2F37]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
References
Ref 1 METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas. J Clin Endocrinol Metab. 2022 Jan 1;107(1):136-149. doi: 10.1210/clinem/dgab652.